Illumina, Inc.
Moat Score — Illumina, Inc.
Total Moat Score
19 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Illumina holds deep, proprietary sequencing-by-synthesis chemistry (XLEAP-SBS) and a large patent estate built over two decades, giving it a technology lead that long-read rivals like PacBio and Oxford Nanopore have struggled to fully replicate in cost-effective short-read workflows. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Illumina's massive installed base and manufacturing scale let it produce flow cells and reagents more cheaply per genome than smaller long-read specialists, though BGI and other lower-cost Asian sequencing suppliers erode this advantage in some international markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Once a lab validates assays and clinical workflows on Illumina's chemistry, the company retains real pricing power on consumables, though large academic and pharma customers negotiate volume pricing and increasingly credible long-read alternatives cap how far pricing can be pushed. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 2 / 5 | A broad base of Illumina-sequenced genomic data and reference databases makes the platform more useful for comparative and population genomics as more customers adopt it, but this effect is modest next to true multi-sided network businesses and does not by itself lock out alternative platforms. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Labs and clinical diagnostics customers build validated assays, LIMS integrations, and regulatory submissions around Illumina's specific instruments and chemistry; re-validating a sequencing workflow on a competing platform is costly and slow, especially in regulated clinical settings. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The global short-read NGS market supports only a handful of scaled players profitably given the R&D intensity required (Illumina spends ~27% of revenue on R&D), but Thermo Fisher's breadth and well-funded long-read entrants show the ceiling on exclusivity is not absolute. |